CorWave, a French medical technology company that develops innovative implantable cardiac support devices for patients suffering from heart failure, has obtained patent from the United States Patent and Trademark Office: ‘Implantable pump system having an undulating membrane’.

The patent describes the application of CorWave’s technology for blood pumping in a left ventricular assist device (LVAD), and specific designs related to using the wave membrane technology to make a blood pump.  This patent completes CorWave’s extended IP portfolio across four patent families.  

CorWave wave membrane technology can mimic a pulse and produce blood flow velocity similar to that of a real heart. Closer to the natural functioning of the heart, CorWave pumps are said to have the potential to reduce the risk of complication and cost. Despite the numerous limitations of the current technologies, the LVAD market already represents about one billion of sales globally. 

“This is a significant milestone for the company and the R&D group. We have been working hard at the forefront of the technological frontier to bring CorWave’s novel pumping technology to the LVAD space. The receipt of this patent reinforces the unique nature of the wave technology,” commented Carl Botterbusch, CorWave.